These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

154 related articles for article (PubMed ID: 8143220)

  • 81. Effects of amiodarone and its active metabolite desethylamiodarone on the ventricular defibrillation threshold.
    Zhou L; Chen BP; Kluger J; Fan C; Chow MS
    J Am Coll Cardiol; 1998 Jun; 31(7):1672-8. PubMed ID: 9626850
    [TBL] [Abstract][Full Text] [Related]  

  • 82. Probability of successful defibrillation at multiples of the defibrillation energy requirement in patients with an implantable defibrillator.
    Strickberger SA; Daoud EG; Davidson T; Weiss R; Bogun F; Knight BP; Bahu M; Goyal R; Man KC; Morady F
    Circulation; 1997 Aug; 96(4):1217-23. PubMed ID: 9286952
    [TBL] [Abstract][Full Text] [Related]  

  • 83. The Arrhythmogenicity of Sotalol and its Role in Heart Failure: A Literature Review.
    Augustin N; Alvarez C; Kluger J
    J Cardiovasc Pharmacol; 2023 Aug; 82(2):86-92. PubMed ID: 37229640
    [TBL] [Abstract][Full Text] [Related]  

  • 84. Endothelin-1 gene polymorphism in patients with malignant arrhythmias.
    Kozák M; Izákovicová Hollá L; Krivan L; Vasků A; Sepsi M; Semrád B; Vácha J
    J Cardiovasc Pharmacol; 2004 Nov; 44 Suppl 1():S92-5. PubMed ID: 15838369
    [TBL] [Abstract][Full Text] [Related]  

  • 85. [Present status in and prospects for anti-arrhythmic drug therapy: How to use type III anti-arrhythmic agents].
    Fujiki A
    Nihon Naika Gakkai Zasshi; 2006 Feb; 95(2):253-60. PubMed ID: 16536075
    [No Abstract]   [Full Text] [Related]  

  • 86. The Selective Late Sodium Current Inhibitor Eleclazine, Unlike Amiodarone, Does Not Alter Defibrillation Threshold or Dominant Frequency of Ventricular Fibrillation.
    Silva AF; Bonatti R; Batatinha JA; Nearing BD; Zeng D; Belardinelli L; Verrier RL
    J Cardiovasc Pharmacol; 2017 Mar; 69(3):178-182. PubMed ID: 28045761
    [TBL] [Abstract][Full Text] [Related]  

  • 87. Expanding clinical role of unique class III antiarrhythmic effects of sotalol.
    Singh BN
    Am J Cardiol; 1990 Jan; 65(2):84A-88A. PubMed ID: 2403738
    [TBL] [Abstract][Full Text] [Related]  

  • 88. Hypertrophic cardiomyopathy with massive hypertrophy, amiodarone treatment and high defibrillation threshold at cardioverter-defibrillator implant.
    Boriani G; Rapezzi C; Biffi M; Branzi A
    Int J Cardiol; 2002 May; 83(2):171-3. PubMed ID: 12007691
    [No Abstract]   [Full Text] [Related]  

  • 89. Comparative hemodynamic effects of amiodarone, sotalol, and d-sotalol.
    Twidale N; Roberts-Thomson P; McRitchie RJ
    Am Heart J; 1993 Jul; 126(1):122-9. PubMed ID: 8322653
    [TBL] [Abstract][Full Text] [Related]  

  • 90. [Possibility of differentiated treatment of ventricular heart rate disturbances based on mechanism of their development].
    Olesin AI; Shabrov AV; Sinenko VI; Popik GS; Boldueva SA; Leonova IA; Poloskina OA
    Kardiologiia; 2005; 45(5):57. PubMed ID: 16007055
    [No Abstract]   [Full Text] [Related]  

  • 91. Intravenous Sotalol: An Under Used Treatment Strategy.
    Kerin NZ
    Cardiology; 2018; 140(3):143-145. PubMed ID: 30016794
    [TBL] [Abstract][Full Text] [Related]  

  • 92. Effects of the beta-adrenoceptor-blocking agent Sotalol on ventricular arrhythmias in patients with chronic ischemic heart disease. A placebo-controlled, double-blind cross-over study.
    Burckhardt D; Pfisterer M; Hoffmann A; Burkart F; Emmenegger H; Jost M; Bolli P; Buehler FR
    Cardiology; 1983; 70 Suppl 1():114-21. PubMed ID: 6342778
    [No Abstract]   [Full Text] [Related]  

  • 93. [Chronic administration of beta blocking agents: left ventricular hemodynamics in myocardial infarctions during exercise (author's transl)].
    Blümchen G; Esche HH
    Z Kardiol; 1981 Sep; 70(9):678-86. PubMed ID: 7303806
    [No Abstract]   [Full Text] [Related]  

  • 94. [Effects of sotalol on ventricular function].
    Guadalajara JF; Guerrero Sierra J; Fishleder BL; Sánchez Torres G; Friedland C
    Arch Inst Cardiol Mex; 1980; 50(2):203-9. PubMed ID: 7416869
    [TBL] [Abstract][Full Text] [Related]  

  • 95. [Study of the antiarrhythmic effects of Sotalol given orally].
    Fauchier JP; Neel C; Garabedian V; Cosnay P; Brochier M
    Ann Cardiol Angeiol (Paris); 1982 Jun; 31(4):329-38. PubMed ID: 7137863
    [No Abstract]   [Full Text] [Related]  

  • 96. Clinical use of automatic implantable defibrillators.
    Leclercq JF; Menasché P; Laborde F; Coumel P; Piwnica A; Slama R
    Eur Heart J; 1987 Aug; 8 Suppl D():143-7. PubMed ID: 3678254
    [TBL] [Abstract][Full Text] [Related]  

  • 97. Sotalol-induced delayed ventricular repolarization in man.
    Edvardsson N; Hirsch I; Emanuelsson H; Pontén J; Olsson SB
    Eur Heart J; 1980 Oct; 1(5):335-43. PubMed ID: 7274246
    [No Abstract]   [Full Text] [Related]  

  • 98. Sotalol prolongation of the QTc interval in hypertensive patients.
    Neuvonen PJ; Elonen E; Tanskanen A; Tuomilehto J
    Clin Pharmacol Ther; 1982 Jul; 32(1):25-32. PubMed ID: 7083728
    [TBL] [Abstract][Full Text] [Related]  

  • 99. [Therapy of drug-resistant ventricular arrhythmias].
    Lessem JN; Hamby RA
    Fortschr Med; 1986 Nov; 104(41):784-6. PubMed ID: 3804148
    [No Abstract]   [Full Text] [Related]  

  • 100. Prolonged Q-T interval and severe tachyarrhythmias, common features of sotalol intoxication.
    Neuvonen PJ; Elonen E; Vuorenmaa T; Laakso M
    Eur J Clin Pharmacol; 1981; 20(2):85-9. PubMed ID: 7262178
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 8.